CRFBP-CRF2 Allosteric Modulation for Alcohol Use Disorder
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alcohol use disorder (AUD) are inadequate, with pharmacotherapies like disulfiram, naltrexone, and acamprosate showing only modest effects and significant limitations, highlighting a critical need for more effective therapeutics.
Innovation Solution
Development of negative allosteric modulators (NAMs) targeting the corticotropin releasing factor binding protein (CRFBP)-CRF2 complex to antagonize CRF-induced potentiation of N-Methyl-D-aspartic acid receptor (NMDAR)-mediated synaptic transmission in dopamine neurons, using compounds such as MLS-0046818 and MLS-0219419.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacotherapies (disulfiram, naltrexone, acamprosate) are used for AUD treatment, then some therapeutic effect is achieved, but the efficacy is marginal and limitations are significant
Solution Approach 1:
The patent changes the molecular target parameter from conventional AUD treatment targets to the CRFBP-CRF2 complex, specifically targeting the C-terminal fragment (10 kD) of CRFBP. This parameter change enables selective modulation of CRF signaling pathways that are critical for alcohol consumption, achieving superior efficacy compared to existing therapies while maintaining safety profile
Solution Approach 2:
The patent introduces negative allosteric modulators (NAMs) as intermediary compounds that bind to the CRFBP-CRF2 complex. These NAMs (such as MLS-0046818 and MLS-0219419) act as mediators to inhibit CRF-induced potentiation of NMDAR-mediated synaptic transmission, thereby reducing alcohol consumption without the significant limitations of current treatments
2Productivity
If CRFBP(10 kD) is fused with CRF2α to create a chimera for HTS, then high-throughput screening of 350,000 small molecules is enabled, but the complexity of the assay system increases
Solution Approach 1:
The patent merges the CRFBP(10 kD) fragment with the CRF2α receptor to create a chimeric protein complex that can be expressed in cell-based assays. This merging enables the simultaneous detection of CRF binding and signaling through a single assay system, facilitating high-throughput screening of 350,000 small molecules while maintaining assay feasibility through standardized cell-based platforms
Solution Approach 2:
The patent creates a simplified model system by expressing the CRFBP-CRF2 chimera in heterologous cells (such as HEK293 cells), allowing the complex biological interaction to be copied and studied in a controlled laboratory setting. This copying approach enables automated high-throughput screening while maintaining the essential biological functionality of the CRF signaling pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NAMs selectively inhibit CRF-induced potentiation of NMDAR in the ventral tegmental area, providing a potential for more effective treatment of AUD by reducing alcohol consumption and promoting abstinence.
Implementation Method 1
identification of negative allosteric modulators (NAMs) of the CRFBP(10 kD)-CRF2 complex that blunt CRF-induced potentiation of N-Methyl-D-aspartic acid receptor (NMDAR)-mediated synaptic transmission
Implementation Method 2
A novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(10 kD)] was developed and found to potentiates CRF-intracellular Ca2+ release
Data Source
AI summary
Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP(27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP(10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2, a cell-based assay was miniaturized, wherein CRFBP(10 kD) was fused as a chimera with CRF2α, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules. This resulted in the identification of negative allosteric modulators (NAMs) of the CRFBP(10 kD)-CRF2 complex that blunt CRF-induced potentiation of N-Methyl-D-aspartic acid receptor (NMDAR)-mediated synaptic transmission in dopamine neurons in the ventral tegmental area (VTA). These results provide the first evidence of specific roles for CRF2 and CRFBP in the modulation of neuronal activity and suggest that NMDARs in the VTA may be a target for the treatment of stress and substance abuse disorders such as alcohol use disorder.